Tumor-associated inflammation (TAI) is a feature of essentially all cancers and can confer
both tumor-promoting and-suppressive functions. Cancer-associated fibroblasts (CAF) …

A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

Tumor microenvironments (TMEs) influence cancer progression but are complex and often
differ between patients. Considering that microenvironment variations may reveal rules …

The heterogeneity of the tumour immune microenvironment (TIME), organized by various
immune and stromal cells, is a major contributing factor of tumour metastasis, relapse and …

Background & Aims The tumour microenvironment (TME) is a crucial mediator of cancer
progression and therapeutic outcome. The TME subtype correlates with patient response to …

Tumor progression is accompanied by fibrosis, a condition of excessive extracellular matrix
accumulation, which is associated with diminished antitumor immune infiltration. Here we …

Neutrophils, the most abundant and efficient defenders against pathogens, exert opposing
functions across cancer types. However, given their short half-life, it remains challenging to …

Immune checkpoint inhibitor (ICI) therapy can induce complete responses in mismatch
repair-deficient and microsatellite instability-high (d-MMR/MSI-H) colorectal cancers (CRCs) …

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …

Cancer-associated fibroblasts (CAFs) are a heterogeneous cell population that plays a
crucial role in remodeling the tumor microenvironment (TME). Here, through the integrated …